A Long-acting Naltrexone Implant (iSTEP-N) for Opioid Use Disorder
At the 9.6 g dose, iSTEP-N provided sustained therapeutic naltrexone exposure for 12 weeks with a favorable safety profile, while releasing less than one-fourth of its drug content. Further studies will evaluate longer-term exposure, safety, and clinical feasibility in individuals with opioid use disorder.
Authors
- Jeffrey D. Benner (ORCID: https://orcid.org/0000-0002-0350-2204)
- Janet H. Ransom (ORCID: https://orcid.org/0000-0002-6765-3933)
- Todd Bertoch (ORCID: https://orcid.org/0000-0001-9896-5238)
- Jonathan Berman
- Pravin Soni
- Steven M. Cohen
- William R. Ravis
Institutions
- Office of the Director (US)
- Io Therapeutics (United States) (US)
- NIHR Research Delivery Network (GB)
- Auburn University (US)
- Salisbury University (US)
Publication Details
- Journal
- Journal of Addiction Medicine
- Published
- 2026-01-26
- DOI
- https://doi.org/10.1097/adm.0000000000001654
- Primary Topic
- Opioid Use Disorder Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00